PDF(Pubmed)
Abstract：
Metastatic melanoma is an aggressive skin cancer with high mortality and recurrence rates. Despite the clinical success of recent immunotherapy approaches, prevailing resistance rates necessitate the continued development of novel therapeutic options. Photoimmunotherapy (PIT) is emerging as a promising immunotherapy strategy that uses photodynamic therapy (PDT) to unleash systemic immune responses against tumor sites while maintaining the superior tumor-specificity and minimally invasive nature of traditional PDT. In this review, we discuss recent advances in PIT and strategies for the management of melanoma using PIT. PIT can strongly induce immunogenic cell death, inviting the concomitant application of immune checkpoint blockade or adoptive cell therapies. PIT can also be leveraged to selectively remove the suppressive immune populations associated with immunotherapy resistance. The modular nature of PIT therapy design combined with the potential for patient-specific antigen selection or drug co-delivery makes PIT an alluring option for future personalized melanoma care.
摘要：
转移性黑色素瘤是一种侵袭性皮肤癌，死亡率和复发率高。尽管最近的免疫治疗方法在临床上取得了成功，普遍的耐药率需要继续开发新的治疗方案。光免疫疗法（PIT）正在成为一种有前途的免疫疗法策略，它使用光动力疗法（PDT）来释放针对肿瘤部位的全身免疫反应，同时保持传统PDT的优异的肿瘤特异性和微创性。在这次审查中,我们讨论了PIT的最新进展以及使用PIT治疗黑色素瘤的策略.PIT可以强烈诱导免疫原性细胞死亡，邀请免疫检查点阻断或过继细胞疗法的伴随应用。还可以利用PIT来选择性地去除与免疫疗法抗性相关的抑制性免疫群体。PIT治疗设计的模块化性质与患者特异性抗原选择或药物共同递送的潜力相结合，使PIT成为未来个性化黑色素瘤护理的诱人选择。
